|
JSM Activity #371This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions. To View the Program: You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time. |
|
|
Legend: = Applied Session,
= Theme Session,
= Presenter |
371 | Wed, 8/10/05, 10:30 AM - 12:20 PM | MCC-200 ABC |
Late Breaking Session 2 -- The Cox-2 Inhibitors Story: What Do (Should) We Know and When Do (Should) We Know It--and What Should We Do About It? | ||
ASA, ENAR, IMS, SSC, WNAR, Biopharmaceutical Section, Biometrics Section, Section on Risk Analysis | ||
Organizer(s): Susan Ellenberg, University of Pennsylvania | ||
Chair(s): Susan Ellenberg, University of Pennsylvania | ||
10:35 AM | A Metaanalysis of Effects of COX-2 Inhibitors — Patricia Kearney, University of Oxford | |
11:05 AM | Chronology of Clinically Important Cardiovascular (CV) Event Data in the Rofecoxib (VIOXX) Development Program — Raymond Bain, Merck & Co., Inc. | |
11:35 AM | Disc: Stephen J.W. Evans, London School of Hygiene and Tropical Medicine | |
11:50 AM | Disc: Robert O'Neill, U.S. Food and Drug Administration | |
12:05 PM | Floor Discussion | |
JSM 2005
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |